| Biomarker ID | 1151 |
| PMID | 23824564 |
| Year | 2013 |
| Biomarker | Histidine; Glycine; Alanine; Kynurenine; Glutamate; Glycerol 3-phosphate (G3P); Betaine; Pipecolate 2-methylbutyrylcarnitin; Isobar: 15-methylpalmitate; 2-methylpalmitate; Threonine; Cytidine 50-diphosphocholine; Valine; Myristoleate (14:1n5); S-adenosylhomocysteine (SAH); Phosphate; Choline; 2-aminobutyrate 2-hydroxypalmitate; Glycerol; Adenine; 2-hydroxystearate; Deoxycarnitine; Fumarate; Docosadienoate (22:2n6); |
| Biomarker Basis | Concentration Based |
| Biomolecule | Metabolites |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Increased with Upgraded Gleason Score |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Gleason Score Upgrading [6 to 7 (3+4) to 7(4+3) to 8] |
| Type of Biomarker | Prognostic |
| Cohort | 260 patients with Prostate cancer such that Gleason Score 6 = 120; 7 (3+4) = 95; 7 (4+3) = 28; and Gleason Score ≥ 8 = 17 were chosen |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | gas chromatography-mass spectrometry (GC–MS) |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |